by Jorge Aura
The biopharmaceutical sector is living a speculation
moment. The general feeling among investors is that great advances with the
fight against cancer are going to be produced and the existing medication will
be improved. Some companies conduct promising studies against cancer. It is
speculated that before 10 years we could have a substantial improvement in the
partial cure of the most deadly cancers. Meanwhile, other companies are trying
to improve the current medication for the retinal and macular degeneration and
COVID19 vaccines.
In the next article I will write about the reasons to
take a speculative position in these companies.
1. Ocugen Inc.
is a biopharmaceutical company focused on discovering,
developing and commercializing transformative therapies to treat blindness
diseases. Our breakthrough modifier gene therapy platform has the potential to
treat multiple retinal diseases with one drug – “one to many”. And our novel
biologic product candidate aims to offer better therapy to patients with
underserved diseases such as wet age-related macular degeneration, diabetic
macular edema and diabetic retinopathy.
Pipeline Portfolio
(Source)
New catalyst
Last February 2, 2021, Ocugen Inc and Bharat Biotech
Announce Execution of Definitive Agreement for the Commercialization of
COVAXIN™ in the US Market.
(Source)
Next Catalyst
- Phase III results of Covaxin early March 2021.
Fundamentals Analysis
OCGN Short Interest
|
SETTLEMENT DATE |
SHORT INTEREST |
AVG. DAILY SHARE
VOLUME |
DAYS TO COVER |
|
01/15/2021 |
14,803,511 |
47,577,579 |
1 |
|
12/31/2020 |
17,658,831 |
187,375,800 |
1 |
|
12/15/2020 |
4,978,581 |
13,895,745 |
1 |
(Source)
Analyst Research
Strong Buy
Based on 4 analysts offering recommendations for ocgn in the last 3 months.
(Source)
Chart Analysis
- Rsi marks an overbought. The stock is in a bullish
channel. The MACD and Full STO marks an upward trend.
2. Salarius Pharmaceuticals Inc
It is an emerging
biotechnology company developing targeted therapies to treat pediatric and
other cancers, including advanced solid tumors. The lead compound Seclidemstat
represents a potential paradigm shift in the treatment of cancer and we are
initially targeting Ewing sarcoma, a devastating pediatric, adolescent and
young adult bone cancer where no targeted therapies are currently available.
Salarius
pharmaceutical ongoing two clinical trials with catalysts in 2021.
Salarius ongoing a
Phase 1 trial in Ewing sarcoma. Ewing sarcoma is a devastating pediatric
illness and represents a major unmet clinical need. Currently, chemotherapy,
radiation and tumor resection surgery are the only options for patients, and in
many cases the tumors reoccur or is in too delicate of a location to risk
surgery. There is a 70-90% five-year mortality rate for patients whose tumors
recur after treatment or who are initially diagnosed with metastatic disease.
Translocations involving the EWS gene are the sole driver for over 85% of Ewing
sarcoma, and the EWS protein must complex with LSD1 to induce a cancer
phenotype. Seclidemstat blocks this LSD1-EWS interaction to reverse cancer
pathology resulting in cures in animal models.
Phase 1 trial in
advanced solid tumors enroll patients with advanced solid tumors who have
progressed on prior therapy, for example patients with prostate, breast,
ovarian, lung and other sarcomas. Depending on the cancer, LSD1 can associate
with a myriad of proteins to drive tumor growth. For instance, in prostate
cancer LSD1 can associate with the androgen receptor to activate genes that
promote cancer cell growth and metastasis. Seclidemstat is able to block these
interactions and reduce tumor burden.
Pipeline Portfolio
(Source)
Next Catalyst
- The company announced in its presentation to
investors that it has the following catalysts for 2021:
(Source)
Fundamentals Analysis
SLRX Short Interest
|
SETTLEMENT DATE |
SHORT INTEREST |
AVG. DAILY SHARE
VOLUME |
DAYS TO COVER |
|
01/15/2021 |
614,252 |
1,797,441 |
1 |
|
12/31/2020 |
572,831 |
510,666 |
1.121733 |
|
12/15/2020 |
466,549 |
2,440,984 |
1 |
(Source)
Analyst Research
Strong Buy
Based on 2 analysts offering
recommendations for slrx in the last 3 months.
(Source)
Chart Analysis
- The MACD and Full STO marks an upward trend. RSI is in a good position.
The stock is in a bullish channel.The moving averages have marked an upward
crossover or golden cross.
*Chart data sourced from stockcharts, all other data
sourced from Nasdaq.com as well as the web of
the previously mentioned company.
Disclosure: I am long SLRX. I
wrote this article myself, and it expresses my own opinions. I am not receiving
compensation for it. I have no business relationship with any company whose
stock is mentioned in this article. Investors buy and/or sell at their own
risk. I declare that I may day-trade any stock at any time mentioned in this
article. For me "long" is until I sell and few tell you that. I do
not "short" stocks and few tell you that too. I have zero connection
to Wall Street and few tell you that too.
